precisionmedicineonline14h
Bristol Myers Squibb Focused on Opdivo SubQ Growth as Q4 Precision Product Sales Increase
Intravenous Opdivo, with $2.48 billion in sales, topped the list of precision oncology products in BMS's growth portfolio.
Indaptus Therapeutics Receives Approval from Health Canada to Expand Clinical Trial of Decoy20
Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical-stage biotechnology company pioneering innovative cancer and viral infection treatments, today announced the ...
Business Wire2d
FDA Approves Genentech’s Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes-Related Blindness
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug ...
MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer
MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer ...
HURA: Initiating an Immune Response
HURA READ THE FULL HURA RESEARCH REPORT We are initiating coverage of TuHURA Biosciences, Inc. (NASDAQ:HURA) with a valuation ...
openaccessgovernment3d
Personalized medicine in oncology: Small molecule inhibitors, biologics and immunotherapies
Priya Hays, Hays Documentation Specialists, discusses innovations and advancements in the development of personalized cancer ...
HCW Biologics Granted FDA Clearance to Evaluate One of the Company’s Lead Product Candidates in a First-In-Human Phase 1 Clinical Trial
Wong, Founder and CEO of HCW Biologics, commented, “The FDA’s clearance to initiate our first-in-human clinical trial for HCW9302 brings us one step closer to advancing a potentially transformative ...